Kevin W. Kuntz
Akebia Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related gene regulation, Epigenetics and DNA Methylation, PARP inhibition in cancer therapy, RNA modifications and cancer, Microtubule and mitosis dynamics
Most-Cited Works
- → Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor(2011)930 cited
- → Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2(2013)768 cited
- → A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells(2012)756 cited
- → Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas(2010)676 cited
- → Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma(2014)520 cited
- → Ti-Catalyzed Enantioselective Addition of Cyanide to Imines. A Practical Synthesis of Optically Pure α-Amino Acids(1999)235 cited
- → Total Synthesis of Anti-HIV Agent Chloropeptin I(2003)176 cited
- → PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity(2021)174 cited
- → The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat(2016)166 cited
- → Search for Chiral Catalysts Through Ligand Diversity: Substrate‐Specific Catalysts and Ligand Screening on Solid Phase(1997)142 cited